The impact of PET and PET/CT on treatment planning and prognosis of patients with NSCLC treated with radiation therapy

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 56, Issue 2, 2012, Pages 191-201

  Nawara, C ^a   Rendl, G ^a   Wurstbauer, K ^a   Lackner, B ^a   Rettenbacher, L ^a   Datz, L ^a   Studnicka, M ^a   Sedlmayer, F ^a   Pirich, C ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Carcinoma, non small cell lung; Positron emission tomography; Tomography, X ray computed

Indexed keywords

CARBOPLATIN; CISPLATIN; FLUORODEOXYGLUCOSE F 18;

AGE; AGED; ARTICLE; ATELECTASIS; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; FEMALE; GENDER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL DEVICE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT PLANNING; WEIGHT REDUCTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, IMAGE-GUIDED; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84864379795     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Janssen-Heijnen MLG, Coebergh JWW. Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 2001;31:123-37. (Pubitemid 32109237)
2. Goodgame B, Pillot GA, Yang Z, Shriki J, Meyers BF, Zoole J et al. Prognostic value of preoperative positron emission tomography in resected stage I non-small cell lung cancer. J Thorac Oncol 2008;3:130-4. (Pubitemid 351323186)
3. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 2005;23:5910-7.
4. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L et al. Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004;46:87-98. (Pubitemid 39201387)
5. Ichinose Y, Yano T, Asoh H, Yokoyama H, Yoshino I, Katsuda Y. Prognostic factors obtained by a pathologic examination in completely resected non-small-cell lung cancer. An analysis in each pathologic stage. J Thorac Cardiovasc Surg 1995;110:601-5.
6. Martini N, Rusch VW, Bains MS, Kris MG, Downey RJ, Flehinger BJ et al. Factors influencing ten-year survival in resected stages I to IHa non-small cell lung cancer. J Thorac Cardiovasc Surg 1999;117:32-6.
7. Okada M, Nishio W, Sakamoto T, Harada H, Uchino K, Tsubota N. Long-term survival and prognostic factors of five-year survivors with complete resection of non-small cell lung carcinoma. J Thorac Cardiovasc Surg 2003;126:558-62. (Pubitemid 37048526)
8. Hicks RJ, Kalff V, MacManus MP, Ware RE, Hogg A, McKenzie AF et al. F-18-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. Journal of Nuclear Medicine 2001;42:1596-604. (Pubitemid 33131317)
9. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43:39-45. (Pubitemid 34101186)
10. Keidar Z, Haim N, Guralnik L, Wollner M, Bar-Shalom R, Ben Nun A et al. PET/CT using F-18-FDG in suspected lung cancer recurrence: Diagnostic value and impact on patient management. Journal of Nuclear Medicine 2004;45:1640-6. (Pubitemid 47618469)
11. Lardinois D, Weder W, Hany TF, Kamel EM, Korom S, Seifert B et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 2003;348:2500-7. (Pubitemid 36706537)
12. Van Der Wel A, Nijsten S, Hochstenbag M, Lamers R, Boersma L, Wanders R et al. Increased therapeutic ratio by (18)FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non-small-cell lung cancer: A modeling study. Int J Rad Oncol Biol Physics 2005;61:649-55. (Pubitemid 40247958)
13. Yang W, Fu Z, Yu J, Yuan S, Zhang B, Li D et al. Value of PET/CT versus enhanced CT for locoregional lymph nodes in non-small cell lung cancer. Lung Cancer 2008;61:35-43.
14. Yi CA, Lee KS, Kim BT, Choi JY, Kwon OJ, Kim H et al. Tissue characterization of solitary pulmonary nodule: comparative study between helical dynamic CT and integrated PET/CT. J Nucl Med 2006;47:443-50. (Pubitemid 46768487)
15. Ashamalla H, Rafla S, Parikh K, Mokhtar B, Goswami G, Kambam S et al. The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer. International Journal of Radiation Oncology Biology Physics 2005;63:1016-23. (Pubitemid 41505278)
16. Nestle U, Walter K, Schmidt S, Licht N, Nieder C, Motaref B et al. F-18-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. International Journal of Radiation Oncology Biology Physics 1999;44:593-7. (Pubitemid 29258434)
17. Pieterman RM, van Putten JWG, Meuzelaar JJ, Mooyaart EL, Vaalburg W, Koeter GH et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. New Engl J Med 2000;343:254-61. (Pubitemid 30490393)
18. Boucher L, Rodrigue S, Lecomte R, Benard F. Respiratory gating for 3-dimensional PET of the thorax: Feasibility and initial results. J Nucl Med 2004;45:214-9. (Pubitemid 47618639)
19. Vesselle H, Freeman JD, Wiens L, Stern J, Nguyen HQ, Hawes SE et al. Fluorodeoxyglucose uptake of primary non-small cell lung cancer at positron emission tomography: new contrary data on prognostic role. Clin Cancer Res 2007;13:3255-63. (Pubitemid 46944910)
20. Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C et al. Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 2008;3:6-12.
21. van der Heijden HFM, Pruim J, Dalesio O, Oyen WJG, Groen HJM. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: A two-center study. J Thorac Oncol 2007;2:1007-12. (Pubitemid 350059576)
22. Jeong HJ, Min JJ, Park JM, Chung JK, Kim BT, Jeong JM et al. Determination of the prognostic value of [F-18]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nuclear Medicine Communications 2002;23:865-70.
23. Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: Correlations and prognostic values. Eur J Radiol 2007;62:214-9. (Pubitemid 46560344)
24. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K et al. [F-18] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-43. (Pubitemid 46202269)
25. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GJ et al. Prognostic importance of the standardized uptake value on F-18-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. J Clin Oncol 1999;17:3201-6. (Pubitemid 29470652)
26. Fox JL, Rengan R, O'Meara W, Yorke E, Erdi Y, Nehmeh S et al. Does registration of pet and planning CT images decrease interobserver and intraobserver variation in delineating tumor volumes for non-small-cell lung cancer? Int J Radiation Oncol Biol Physics 2005;62:70-5. (Pubitemid 40591925)
27. Verboom P, van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ et al. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003;30:1444-9. (Pubitemid 37356109)
28. Hoang JK, Hoagland LF, Coleman RE, Coan AD, Herndon JE, Patz EF, Jr. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. J Clin Oncol 2008;26:1459-64.
29. Wurstbauer K, Deutschmann H, Kopp P, Kranzinger M, Merz F, Nairz O et al. NSCLC: primary tumor size-radiation dose-related accelerated, twice daily radiotherapy by target splitting, preceded by 2 cycles of chemotherapy - first results of a prospective study. Strahlenther Onkol 2007Dec;183 Spec No 2:38-40. PubMed PMID: 18167008.
30. Wurstbauer K, Deutschmann H, Kopp P, Sedlmayer F. Radiotherapy planning for lung cancer: slow CTs allow the drawing of tighter margins. Radiother Oncol 2005;75:165-70. (Pubitemid 40805245)
31. van Tinteren H, Hoekstra OS, Smit EF, van den Bergh JH, Schreurs AJ, Stallaert RA et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer: the PLUS multicentre randomised trial. Lancet 2002;359:1388-93.
32. Pottgen C, Levegrun S, Theegarten D, Marnitz S, Grehl S, Pink R et al. Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res 2006;12:97-106. (Pubitemid 43166182)
33. Lee DH, Han JY, Cho KH, Pyo HR, Kim HY, Yoon SJ et al. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-smallcell lung cancer. Int J Radiat Oncol Biol Phys 2005;63:1037-44.
34. Reboul F, Brewer Y, Vincent P, Chauvet B, Faure CF, Taulelle M. Concurrent cisplatin, etoposide, and radiotherapy for unresectable stage III nonsmall cell lung cancer: a phase II study. Int J Radiat Oncol Biol Phys 1996;35:343-50. (Pubitemid 26158757)
35. Stinchcombe TE, Morris DE, Lee CB, Moore DT, Hayes DN, Halle JS et al. Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformai thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small cell lung cancer. J Thorac Oncol 2008;3:250-7. (Pubitemid 351654324)
36. Sura S, Gupta V, Yorke E, Jackson A, Amols H, Rosenzweig KE. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 2008;87:17-23.
37. Hamberg LM, Hunter GJ, Alpert NM, Choi NC, Babich JW, Fischman AJ. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994;35:1308-12. (Pubitemid 24243143)
38. Keyes JW, Jr. SUV: standard uptake or silly useless value? J Nucl Med. 1995;36:1836-9.
39. Geus-Oei LF, van Krieken JHJM, Aliredjo RP, Krabbe PFM, Frielink C, Verhagen AFT et al. Biological correlates of FDG uptake in non-small cell lung cancer. Lung Cancer 2007;55:79-87. (Pubitemid 46038871)
40. Nestle U, Schaefer-Schuler A, Kremp S, Groeschel A, Hellwig D, Rübe C, Kirsch CM. Target volume definition for 18F-FDG PET-positive lymph nodes in radiotherapy of patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007;34:453-62. (Pubitemid 46426982)
41. Hellwig D, Baum RP, Kirsch C. FDG-PET, PET/CT and conventional nuclear medicine procedures in the evaluation of lung cancer: a systematic review. Nuklearmedizin 2009;48:59-69.
42. Hellwig D, Graeter TP, Ukena D, Groeschel A, Sybrecht GW, Schaefers HJ, Kirsch CM. 18F-FDG PET for mediastinal staging of lung cancer: which SUV threshold makes sense? J Nucl Med 2007;48:1761-6. (Pubitemid 350099319)
43. De Wever W, Ceyssens S, Mortelmans L, Stroobants S, Marchal G, Bogaert J et al. Additional value of PET-CT in the staging of lung cancer: comparison with CT alone, PET alone and visual correlation of PET and CT. Eur Radiol 2007;17:23-32. (Pubitemid 46063025)
44. Cerfolio RJ, Ojha B, Bryant AS, Raghuveer V, Mountz JM, Bartolucci AA. The accuracy of integrated PET-CT compared with dedicated PET alone for the staging of patients with nonsmall cell lung cancer. Ann Thorac Surg 2004;78:1017-23. (Pubitemid 39164825)
45. Silvestri GA, Gould MK, Margolis ML, Tanoue LT, McCrory D, Toloza E et al. American College of Chest Physicians. Noninvasive staging of non-small cell lung cancer: ACCP evidence-based clinical practice guidlines (2nd edition). Chest 2007;132(3 Suppl): 178S-201S. (Pubitemid 47502807)
46. Toloza EM, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003;123(1 Suppl):137S-146S. (Pubitemid 36135711)
47. Shim SS, Lee KS, Kim BT, Chung MJ, Lee EJ, Han J et al. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging. Radiology 2005;236:1011-9. (Pubitemid 41170866)